Medicenna's MDNA11 Shows Best-in-Class Potential in Cancer Trials
Medicenna Therapeutics provides a 2026 outlook, highlighting strong clinical data for MDNA11 in advanced cancer and plans for a new bifunctional therapy, MDNA113. Read the latest on these Canadian biotech advancements.